 |
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of...
Whether you're launching a startup or growing an established brand, understanding intellectual property law is essential. An intellectual property lawyer in Melbourne can guide you through registrat...
Daily Bulletin
For many migrants, bringing in their ageing parents to reside with them in Australia is one of the most significant milestones. However, the visa pathway is not always simple. The daunting prerequisit...
Daily Bulletin
If you’re launching a business in 2025, chances are it’s going to be digital-first. Whether you’re running an online store, offering consulting services, or building something entirely new, they all h...
Daily Bulletin
